

REMARKS:

Applicants respectfully request that previous claims 1-21 submitted with the application, which was filed on September 16, 2003 and any new claims submitted in the Preliminary Amendment of September 16, 2003 be cancelled and that this amendment be entered before Examination.

Applicants filed the present application on September 16, 2003 as Attorney Docket No. 6133.214-US (Serial No. 10/663,463) and filed a second continuation in this patent family on September 17, 2003 as Attorney Docket No. 6133.224-US (Serial No.10/664,368). Unfortunately, the preliminary amendments filed with both cases were identical. Applicants intend to present the claims contained in this preliminary amendment for prosecution in this case (Attorney Docket No. 6133.214-US, Serial No. 10/663,463) and provoke an interference with US Patent 6,544,212 to Galley et al in the other co-pending case (Attorney Docket No. 6133.224-US, Serial No. 10/664,368).

CONCLUSION

Claims 22-48 are now the only claims pending in the instant application. Applicants believe these claims to be in condition for allowance and respectfully request entry of this amendment and Examination and allowance of the pending claims.

The commissioner is authorized to charge any payments related to this application to Novo Nordisk's Deposit Account, No. 14-1447 and to credit any over payments to the same account. Should any petitions for extensions of time be required, applicants respectfully request such petitions and authorize payment of any fees due in connection with them to the above referenced deposit account.

Respectfully submitted,



Marc A. Began, Reg. No. 48,829
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800

Date: October 20, 2003

23650

PATENT TRADEMARK OFFICE